Cardiovascular disease and COVID-19: les liaisons dangereuses

Eur J Prev Cardiol. 2020 Jul;27(10):1017-1025. doi: 10.1177/2047487320924501. Epub 2020 May 11.

Abstract

Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.

Keywords: COVID-19; Coronavirus; SARS-CoV-2; cardiovascular; comorbidities; risk factors.

Publication types

  • Review

MeSH terms

  • COVID-19
  • Cardiovascular Agents / administration & dosage*
  • Cardiovascular Agents / pharmacology
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / epidemiology*
  • Cause of Death*
  • Comorbidity
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / prevention & control
  • Europe / epidemiology
  • Female
  • Humans
  • Male
  • Pandemics / prevention & control
  • Pandemics / statistics & numerical data*
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control
  • Prevalence
  • Risk Assessment
  • Survival Analysis

Substances

  • Cardiovascular Agents